Neurocrine Biosciences, Inc.

How big is Neurocrine Biosciences, Inc.?

As of Jun 18, Neurocrine Biosciences, Inc. has a market capitalization of $12.36 billion, with net sales of $2.41 billion and net profit of $305.80 million over the latest four quarters.

As of Jun 18, Neurocrine Biosciences, Inc. has a market capitalization of 12,358.85 million, categorizing it as a Mid Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2,412.60 million, while the sum of Net Profit for the same period is 305.80 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 2,589.70 million and Total Assets at 3,847.00 million.

What does Neurocrine Biosciences, Inc. do?

Neurocrine Biosciences, Inc. develops pharmaceuticals for neurological and endocrine disorders, with recent net sales of $573 million and a market cap of approximately $12.36 billion. The company operates in the mid-cap pharmaceuticals and biotechnology sector.

Overview:<BR>Neurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals for diseases with unmet medical needs, focusing on neurological and endocrine-based diseases and disorders, and operates within the Pharmaceuticals & Biotechnology industry in the mid-cap market segment.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 573 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 8 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 12,358.85 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 35.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.35 <BR>Return on Equity: 13.90% <BR>Price to Book: 4.87<BR><BR>Contact Details:<BR>Address: 12780 El Camino Real, SAN DIEGO CA : 92130-2042 <BR>Tel: 1 858 6177600 <BR>Fax: 1 858 6177602 <BR>Website: http://www.neurocrine.com/

Should I buy, sell or hold Neurocrine Biosciences, Inc.?

Who are in the management team of Neurocrine Biosciences, Inc.?

As of March 2022, the management team of Neurocrine Biosciences, Inc. includes Dr. William Rastetter (Independent Chairman), Dr. Kevin Gorman (CEO), and several Independent Directors: Mr. Gary Lyons, Mr. George Morrow, Ms. Leslie Norwalk, Mr. Richard Pops, and Ms. Shalini Sharp. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Neurocrine Biosciences, Inc. includes the following individuals:<BR><BR>- Dr. William Rastetter, who serves as the Independent Chairman of the Board.<BR>- Dr. Kevin Gorman, the Chief Executive Officer and a Director.<BR>- Mr. Gary Lyons, an Independent Director.<BR>- Mr. George Morrow, an Independent Director.<BR>- Ms. Leslie Norwalk, an Independent Director.<BR>- Mr. Richard Pops, an Independent Director.<BR>- Ms. Shalini Sharp, an Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Is Neurocrine Biosciences, Inc. technically bullish or bearish?

As of October 31, 2025, Neurocrine Biosciences, Inc. shows a bullish technical trend overall, supported by daily moving averages and monthly MACD, but with caution due to mixed signals from weekly indicators and underperformance against the S&P 500 in the longer term.

As of 31 October 2025, the technical trend for Neurocrine Biosciences, Inc. has changed from mildly bullish to bullish. The daily moving averages indicate a bullish stance, while the monthly MACD supports this with a bullish signal. However, the weekly MACD and KST are mildly bearish, suggesting some short-term weakness. Bollinger Bands are mildly bullish on both weekly and monthly time frames, indicating potential upward movement. Overall, the stock has underperformed the S&P 500 in the year-to-date and three-year periods, but has shown a positive return over the past month. The current technical stance is bullish, but with some caution due to mixed signals in shorter time frames.

Is Neurocrine Biosciences, Inc. overvalued or undervalued?

As of November 21, 2025, Neurocrine Biosciences, Inc. has an attractive valuation grade, indicating it is undervalued with a favorable P/E ratio of 35 and strong ROCE of 30.61%, although it has underperformed the S&P 500 over the past 3 and 5 years despite a recent 1-year return of 12.42%.

As of 21 November 2025, the valuation grade for Neurocrine Biosciences, Inc. has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 35, an EV to EBITDA ratio of 21.72, and a robust ROCE of 30.61%. In comparison to peers, Neurocrine's P/E ratio is more favorable than Viatris, Inc., which has a P/E of 44.86, while Walgreens Boots Alliance, Inc. shows a negative P/E, highlighting Neurocrine's relative strength in the market.<BR><BR>Despite recent stock performance showing a 1-year return of 12.42% compared to the S&P 500's 11.00%, the longer-term picture reveals a significant underperformance over 3 years and 5 years, with returns of 18.73% and 47.43%, respectively, against the S&P 500's 67.17% and 85.61%. This suggests that while Neurocrine is currently attractive, it has lagged behind broader market returns over the longer term.